Status:
TERMINATED
Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion
Lead Sponsor:
Radboud University Medical Center
Conditions:
Malignant Ascites
Malignant Pleural Effusion
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In some patients with cancer there are also cancer cells in the abdominal cavity or between the lung membranes. These cancer cells create too much moisture in the abdominal cavity or between the lung ...
Detailed Description
Malignant ascites is a difficult clinical problem. Increasing intra-abdominal pressure resulting from fluid accumulation may cause anorexia, sleep disturbance, pain, dyspnoea, abdominal distension, fa...
Eligibility Criteria
Inclusion
- Symptomatic malignant ascites and/or pleural effusion (from a histological proven solid malignancy which is refractory to standard anti-tumour therapy of for which no standard therapy exists)
- Karnofsky score ≥ 50 if the low performance score is due to ascites and/or pleural effusion, otherwise ≥ 60
- Age ≥ 18 years
- Written informed consent
Exclusion
- Contraindications for treatment with cediranib:
- The presence of a pleural or peritoneal tap
- Untreated unstable brain or meningeal metastases.
- Previous treatment with chemotherapeutic agents or tyrosine kinase inhibitors (TKIs) within 14 days prior to the first dose of cediranib, with cetuximab within 30 days prior to the first dose of cediranib, or with bevacizumab within 60 days prior to the first dose of cediranib
- Inadequate bone marrow reserve as demonstrated by an absolute neutrophil count ≤1.5 x 109/L or platelet count ≤100 x 109/L
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2,5 x ULN
- Serum creatinine \> 1.5 x ULRR or a creatinine clearance of ≤ 50mL/min calculated by Cockcroft-Gault
- Greater than +1 proteinuria on two consecutive dipsticks taken no less than 1 week apart unless urinary protein \< 1.5g in a 24 hr period
- Prothrombin time (PT) and activated partial thromboplastin time (APTT) \> 2 x ULN History of significant gastrointestinal impairment, as judged by the Investigator, that would significantly affect the absorption of cediranib, including the ability to swallow the tablet whole. Patients with an ileostoma.
- Patients with a history of poorly controlled hypertension with resting blood pressure \>150/100 in the presence or absence of a stable regimen of anti-hypertensive therapy. Patients who are currently receiving maximal doses of calcium channel blockers or more than 1 antihypertensive for the treatment of hypertension are also ineligible.
- Any evidence of severe or uncontrolled diseases e.g., unstable or uncompensated respiratory, cardiac, hepatic or renal disease.
- Unresolved toxicity \> CTC grade 1 from previous anti-cancer therapy (including radiotherapy) except alopecia (if applicable) or polyneuropathy.
- Mean QTc with Bazetts correction \>470msec in screening ECG or history of familial long QT syndrome
- Significant haemorrhage (\>30mL bleeding/episode in previous 3 months) or haemoptysis (\>5mL fresh blood in previous 4 weeks)
- Recent (\<14 days) major surgery prior to entry into the study, or a surgical incision that is not fully healed
- Pregnant or breast-feeding women or women of childbearing potential with a positive pregnancy test prior to receiving study medication
- Known risk of the patient transmitting HIV, hepatitis B or C via infected blood
- Treatment with an investigational (non-registered) drug within 30 days prior to the first dose of cediranib
- Other concomitant anti-cancer therapy (including LHRH agonists) except steroids
- Concomitant use of any medication that may significantly affect hepatic cytochrome P450 drug metabolising activity by way of enzyme induction (e.g., phenytoin) or inhibition (e.g., ketoconazole, ritonavir, erythromycin) within 2 weeks if the first dose of cediranib and throughout the study period
- Patients being treated with anticoagulants (with the exception of low molecular weight heparin).
- Patients previously treated with anthracyclines (total of \> 550 mg/m2 doxorubicine) and an ejection fraction on the MUGA scan below 40%
Key Trial Info
Start Date :
April 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01262612
Start Date
April 1 2010
Last Update
July 15 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Centre Nijmegen
Nijmegen, Gelderland, Netherlands, 6500 HB